First add-on perampanel for focal-onset seizures: An open-label, prospective study.

ABSTRACT:

Objectives

This study aimed to determine the efficacy and safety of perampanel added to monotherapy in patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.

Materials & methods

In this multicentre, open-label trial, enrolled patients were treated with perampanel monotherapy. During a 12-week titration period, perampanel was incrementally increased by 2 mg/d over ≥2-week intervals. Patients then entered a 24-week maintenance period. The primary objective was to investigate the 50% responder rate in total seizure frequency, with 75% and 100% responder rates as secondary objectives. Treatment-emergent adverse events (TEAEs) and adverse drug reactions were recorded. A post hoc analysis was performed to investigate the effect of titrat

SUBMITTER: Kim JH 

PROVIDER: S-EPMC6973118 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature